About the relationship of rosacea-like dermatitis
- Authors: Bakulev A.L.1, Bakuleva M.V.2
-
Affiliations:
- Central State Medical Academy, Department of Presidential Affairs
- LLC SB Cosmetology Clinic
- Issue: Vol 98, No 6 (2022)
- Pages: 101-106
- Section: GUIDELINES FOR PRACTITIONERS
- URL: https://journals.rcsi.science/0042-4609/article/view/117645
- DOI: https://doi.org/10.25208/vdv1376
- ID: 117645
Cite item
Full Text
Abstract
The literature review is devoted to the problem of rosacea-like dermatitis developing in patients with rosacea against the background of irrational uncontrolled use of topical glucocorticosteroids or cosmetics. The clinical picture of the combined pathology consists of symptoms characteristic of both diseases, which makes diagnosis difficult.
Management tactics of patients with combined pathology, first of all, involves the elimination of symptoms of rosacea–like dermatitis, dominating the clinical picture, using metronidazole, calcineurin inhibitors, azelaic acid, in severe cases — low doses of systemic isotretinoin. The possibility of using activated zinc pyrithione, which has antimicrobial, anti-fungal and anti-inflammatory effects, as a topical remedy to eliminate the symptoms of rosacea-like dermatitis is discussed.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Andrey L. Bakulev
Central State Medical Academy, Department of Presidential Affairs
Author for correspondence.
Email: al_ba05@mail.ru
ORCID iD: 0000-0002-1450-4942
SPIN-code: 6708-7386
MD, Dr. Sci. (Med.), Professor
Russian Federation, Marshala Timoshenko str., 19, bldg 1A, 121359, MoscowMaria V. Bakuleva
LLC SB Cosmetology Clinic
Email: mahutata@mail.ru
ORCID iD: 0000-0003-4505-4945
SPIN-code: 4834-5800
Cosmetologist, Dermatovenereologist
Russian Federation, Cheluskintsev str., 148, 410012, SaratovReferences
- Lipozenčić J, Hadžavdić SL. Perioral dermatitis. Clin Dermatol. 2014;32(1):125–30. doi: 10.1016/j.clindermatol.2013.05.034
- Самцов А.В., Аравийская Е.Р. Акне и розацеа. М.: Фармтек; 2021. C. 400 [Samtsov AV, Araviiskaya EA. Akne i rozacea (Acne and rosacea). Moscow: Farmtec; 2021. P. 400 (In Russ.)]
- Odom R, Dahl M, Dover J, Draelos Z, Drake L, Macsai M, et al. Standard management options for rosacea, part 1: overview and broad spectrum of care. Cutis. 2009;84(1):43–47.
- Palatsi R, Kelhälä HL, Hägg P. [New insights in the pathogenesis and treatment of rosacea]. Duodecim. 2012;128(22):2327–2335.
- Yamasaki K, Kanada K, Macleod DT, Borkowski AW, Morizane S, Nakatsuji T, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011;131(3):688–697. doi: 10.1038/jid.2010.351
- Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15(1):2–11. doi: 10.1038/jidsymp.2011.7
- Darlenski R, Kazandjieva J, Tsankov N, Fluhr JW. Acute irritant threshold correlates with barrier function, skin hydration and contact hypersensitivity in atopic dermatitis and rosacea. Exp Dermatol. 2013;22(11):752–753. doi: 10.1111/exd.12251
- Meyer-Hoffert U, Schröder JM. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatology Symp Proc. 2011;15(1):16–23. doi: 10.1038/jidsymp.2011.2
- Darlenski R, Kazandjieva J, Tsankov N, Fluhr JW. Acute irritant threshold correlates with barrier function, skin hydration and contact hypersensitivity in atopic dermatitis and rosacea. Exp Dermatol. 2013;22(11):752–753. doi: 10.1111/exd.12251
- Voegeli R, Rawlings AV, Doppler S, Schreier T. Increased basal transepidermal water loss leads to elevation of some but not all stratum corneum serine proteases. Int J Cosmet Sci. 2008;30(6):435–442. doi: 10.1111/j.1468-2494.2008.00472.x
- Bradford LG, Montes LF. Perioral dermatitis and Candida albicans. Arch Dermatol. 1972;105(6):892–895.
- Takiwaki H, Tsuda H, Arase S, Takeichi H. Differences between intrafollicular microorganism profiles in perioral and seborrhoeic dermatitis. Clin Exp Dermatol. 2003;28(5):531–534. doi: 10.1046/j.1365-2230.2003.01349.x
- Dolenc-Voljc M, Pohar M, Lunder T. Density of Demodex folliculorum in perioral dermatitis. Acta Derm Venereol. 2005;85(3):211–225. doi: 10.1080/00015550510030069
- Spirov G, Berova N, Vassilev D. Effect of oral inhibitors of ovulation in treatment of rosacea and dermatitis perioralis in women. Australas J Dermatol. 1971;12:145–154.
- Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587. doi: 10.1067/mjd.2002.120625
- Адаскевич В.П. Периоральный дерматит: клиническая картина, диагностика, лечение. Дерматология. 2008;1:17–20 [Adaskevich VP. Perioral dermatitis: clinical picture, diagnosis, treatment. Dermatologija. 2008;(1):17–20 (In Russ.)]
- Oppel T, Pavicic T, Kamann S, Bräutigam M, Wollenberg A. Pimecrolimus cream (1 %) efficacy in perioral dermatitis — results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol. 2007;21(9):1175–1180. doi: 10.1111/j.1468-3083.2007.02191.x
- Schwarz T, Kreiselmaier I, Bieber T, Thaci D, Simon JC, Meurer M, et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol. 2008;59(1):34–40. doi: 10.1016/j.jaad.2008.03.043
- Rodríguez-Martín M, Sáez-Rodríguez M, Carnerero-Rodríguez A, Rodríguez-García F, Cabrera de Paz R, Sidro-Sarto M, et al. Treatment of perioral dermatitis with topical pimecrolimus. J Am Acad Dermatol. 2007;56(3):529–530. doi: 10.1016/j.jaad.2005.03.011
- Jansen T. Azelaic acid as a new treatment for perioral dermatitis: results from an open study. Br J Dermatol. 2004;151(4):933–934. doi: 10.1111/j.1365-2133.2004.06202.x
- Jansen T, Grabbe S. Perioral dermatitis in childhood — Clinical features, etiopathogenesis and treatment with special reference to own experiences with the use of 20% azelaic acid cream. Aktuelle Dermatologie. 2007;33:180–183.
- Кубанов А.А., Петровский Ф.И. Активированный пиритион цинка (Скин-кап). Механизмы действия. Клиническое применение. Вестник дерматологии и венерологии, 2009;85(5):35–42 [Kubanov AA, Petrovsky FI. Activated zinc pyrithione (Skin cap). Mechanisms of action. Clinical application. Vestnik dermatologii i venerologii, 2009;85(5):35–42 (In Russ.)]
- Фассахов Р.С., Пампура А.Н., Коростовцев Д.С., Сукманская Е.О., Смирнова М.О., Решетникова И.Д., и др. Пиритион цинк (скин-кап) в терапии атопического дерматита у детей (по результатам Российского многоцентрового исследования КАДЕТ). Российский аллергологический журнал. 2007;4(2):75–81 [Fassakhov RS, Pampura AN, Korostovtsev DS, Sukmanskaja EO, Smirnova MO, Reshetnikova ID, et al. Zinc pyrithione (SkinCap) in the treatment of atopic dermatitis in children (according to the results of the Russian multicenter study CADET). Rossijskij Allergologicheskij Zhurnal. 2007;4(2):75–81 (In Russ.)]
- Park M, Cho YJ, Lee YW, Jung WH. Understanding the Mechanism of Action of the Anti-Dandruff Agent Zinc Pyrithione against Malassezia restricta. Sci Rep. 2018;8(1):12086. doi: 10.1038/s41598-018-30588-2
- Мокроносова М.А., Глушакова А.М., Голышева Е.В. Обоснование отсутствия синдрома отмены препарата Скин-кап: антимикотическая активность цинка пиритиона. Клиническая дерматология и венерология. 2008;6(5):69–72 [Mokronosova MA, Glushakova AM, Golysheva EV. Evidence of lack of withdrawal syndrom of pyrithione zinc: antimycotic activity of pyrithione zinc. Klinicheskaja dermatologija i venerologija. 2008;6(5):69–72 (In Russ.)]
Supplementary files
